Naloxone for shock

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2003, Pages

  Boeuf, Benoit ^a   Poirier, Véronique ^b   Gauvin, France ^c   Guerguerian, Anne Marie ^c   Roy, Chantal ^c   Farrell, Catherine ^c   Lacroix, Jacques ^c  

^a Centre Hospitalier Universitaire   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884452616     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004443     Document Type: Review

References (75)

1. De Maria A, Craven DE, Heffernan JJ, McIntosh TK, Grindlinger GA, McCabe WR. Naloxone versus placebo in treatment of septic shock. Lancet 1985;1:1363-5.
2. Hughes GS. Naloxone and methylprednisalone sodium succinate enhance sympathomedullary in patients with septic shock. Life Sciences 1984;35:2319-26.
3. Lu H, Xu G, Sheng Z. Clinical effects of naloxone on hemorrhagic shock. Chung Hua Wai Ko Tsa Chih 1995;33(6):355-8.
4. Montastruc JL, Richard J, Cathala B. Naloxone fails to reverse blood pressure in shock: A double blind study in man. Journal de Pharmacologie 1985;16(2):313-4.
5. Roberts DE, Dobson KE, Hall KW, Light RB. Effects of prolonged naloxone infusion in septic shock. Lancet 1988;2:699-702.
6. Safani M, Blair J, Ross D, Waki R, Li C, Libby G. Prospective, controlled, randomized trial of naloxone infusion in early hyperdynamic septic shock. Critical Care Medicine 1989;17:1004-9.
7. Allolio B, Fischer H, Kalen D, Deub U, Winkelmann W. Naloxon by therapy refractory shock [Naloxon im therapierefraktären Schock]. Klinische Wochenschrift 1986;64:16.
8. Allolio B, Fischer H, Kaulen U, Deus U, Winkelmann W. Naloxone in treatment of circulatory shock resistant to conventional therapy. Klinische Wochenschrift 1987;65:213-17.
9. Bone R, Jacobs E, Wilson F, Hiller F. Naloxone reversal of hypotension: A clinical study. American Review of Respiratory Disease 1982;125:93.
10. Bonnet F, Bilaine J, Lhoste F, Mankijian B, Kerdelhue B, Rapin M. Naloxone therapy of human septic shock. Critical Care Medicine 1985;13:972-5.
11. Canady J, Williams W, Thompson I, Vincent GS, Hoover E. Use of the naloxone in septic shock. Journal of the National Medical Association 1989;81:669-73.
12. Desmonts JM, Bohm G, Couderc E. Hemodynamic responses to low doses of naloxone after narcotic-nitrous oxide anesthesia. Anesthesiology 1978;49:12-6.
13. Duarte RR, Mumtaz M, Youssef N, Nayak P, Grace BW. Effects of naloxone infusion in patients with septic shock and renal failure: A limited experience. American Journal of Nephrology 1992;12:431-6.
14. Estilo AE, Cottrell JE. Hemodynamic and catecholamine changes after administration of naloxone. Anesthesia and Analgesia 1982;61:349-53.
15. Gerad H, Schimpff SC, Kaplan R. Naloxone for refractory hypotension in septic shock. Clinical Research 1983;31:257A.
16. Groeger JS, Carlon GC, Howland WS. Naloxone in septic shock. Critical Care Medicine 1983;11:650-4.
17. Hackshaw KV, Parker GA, Roberts JW. Naloxone in septic shock. Critical Care Medicine 1990;18:47-51.
18. Hughes GS, Porter RS, Mars R, Harker CC. Naloxone and septic shock. Annals of Internal Medicine 1983;98:559.
19. The International Liaison Committee on Resuscitation. The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support. Pediatrics 2006;117(5):e955-977. [DOI: 10.1542/peds.2006-0206]
20. Lightfoot JT, Katz L, DeBate K. Naloxone decreases tolerance to hypotensive, hypovolemic stress in healthy humans. Critical Care Medicine 2000;28:684-91.
21. Martinon JM, Franco A, Garcia JL, Fuster M, Bao A, Martinon F, Pena J. Naloxone hydrochloride in the therapy of endotoxic shock following meningococcal disease. Initial results. Anales Espanoles de Pediatria 1982;17:457-60.
22. Oldroyd KG, Gray CE, Carter R, Harvey K, Borland W, Beastall G, Cobbe SM. Activation and inhibition of the endogenous opioid system in human heart failure. British Heart Journal 1995;73:41-8.
23. Peters WP, Johnson MW, Friedman PA, Mitch WE. Pressor effect of naloxone in septic shock. Lancet 1981;1:529-32.
24. Putterman C, Halperin P, Leykin Y, Sorkine P, Geller B, Bursztein S. Early use of naloxone in shock - A clinical trial. Resuscitation 1986;13:185-90.
25. Rock P, Silverman H, Pump D, Kecala Z, Smith P, Michael JR, Summer W. Efficacy and safety of naloxone in septic shock. Critical Care Medicine 1985;13:28-33.
26. Tarelkina MN, Shirokov, Tsibin IN. Experience with using narcanti (naloxone) in patients with traumatic shock. Vestnik Khirurgii Imou I I Grekova 1989;143:110-2.
27. Veliz Pintos RA, Torres Bedoya MA, Forero Gomez J, Olvera Hidalgo C, Orozco Veraztegui O. Clinical evaluation of the effect of the administration of naloxone in comparison with methylprednisolone in infants with septic shock. Boletin Medico Del Hospital Infantil de Mexico 1985;42:531-40.
28. Accettelli U, Ambrosi F, Russo L, De Petris U, Stagnitti F. Use of naloxone in first aid. Clinica Terapeutica 1982;102:197-201.
29. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20:864-74.
30. Bagrov AY. Plasma beta-endorphin levels in acute myocardial infarction. Annals of Emergency Medicine 1993;22:268-9.
31. Cabrera Sorrosal JE, Montejo Gonzalez JC, Suarez Alvarez JR, Blesa Alpica A, Ferrero Zorita J. Failure of naloxone in septic shock. Critical Care Medicine 1986;14:79-80.
32. Campos JM, Zueras R, Escolano F, Villar Landeira JM. Use of naloxone in the therapy of septic shock. Revista Espanola de Anestesiologia 1986;33:451-3.
33. Cattani F, Grillanda G. Use of naloxone in refractory shock. Recenti Progressi in Medicina 1982;72:647-52.
34. Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials 1981;2:31-49.
35. Christensen MA, Gresch JJ. Use of naloxone in septic shock: A case report and review of current literature. Journal of Burn Care and Rehabilitation 1986;7:122-6.
36. Cocchi P, Silenzi M, Calabri G, Salvi G. Naloxone in fulminant meningococcemia. Pediatric Infectious Diseases 1984;3:187.
37. Cohen KR, Emmons KM, Goldstein MF. Naloxone treatment of toxic shock syndrome. Archives of Internal Medicine 1983;143:1072.
38. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews. Statistics in Medicine 1987;6:245-50.
39. De Groot GH, Schalm SW, Dirksen R, Valk KC, Boks AL. Effect of naloxone on shock in a patient with fulminant hepatic failure. Netherlands Journal of Medicine 1983;26:77-9.
40. Dirksen R, Otten M H, Wood GJ, Verbaan CJ, Haalebos MM, Verdouw PV, Nijhuis GMM. Naloxone in shock. Lancet 1980;1:1360-1.
41. Einarson TR, McGhan WF, Bootman JL, Sabers DL. Meta-analysis: Quantitative integration of independent research results. American Journal of Hospital Pharmacy 1985;42:1957-64.
42. Faden AI, Holaday JW. Opioate antagonists: A role in the treatment of hypovolemic shock. Science 1979;205:317-8.
43. Fleiss JL. Reliability of measurement. In: Fleiss JL editor(s). The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons, 1986:17-31.
44. Furman WL, Menke JA, Barson WJ, Miller RR. Continuous naloxone infusion in two neonates with septic shock. Journal of Pediatrics 1984;105:649-51.
45. Gaudette RR, Browne BJ. Use of naloxone in septic shock. Journal of Emergency Nursing 1986;12:81-4.
46. Gullo A, Romano E. Naloxone and anaphylactic shock. Lancet 1983;1:819.
47. Higgins TL, Sivak ED. Reversal of hypotension with naloxone. Cleveland Clinic Quarterly 1981;48:283-8.
48. Higgins TL, Sivak ED, O'Neil DM, Grave JW, Foutch DG. Reversal of hypotension by continuous naloxone infusion in a ventilator dependent patient. Annals of Internal Medicine 1983;98:47-8.
49. Holiday JW, Faden AI. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature 1978;275:450-1.
50. Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Research 1975;88:295-308.
51. Jessop DS. ß-endorphin in the immune system - mediator of pain and stress. Lancet 1998;351:1828-9.
52. Jolivet M, Laurion M. Shock and the administration of naloxone [Le choc et l'administration de naloxone]. Union Medicale Du Canada 1984;113:783-5.
53. Kramer MS, Feinstein AR. Clinical biostatistic LIV: The biostatistics of concordance. Clinical Pharmacology and Therapeutics 1981;29:111-23.
54. Lefebvre C, Tasiemski A, Salzet M. Opioid peptides, opiated substances and immune response [Peptides opioïdes, substances opiacées et réponse immunitaire]. Médecine/Sciences 2000;16:235-42.
55. Lenz K, Druml W, Gassner A, Hruby K, Kleinberger G, Laggner A. Naloxone in shock. Lancet 1981;1:834.
56. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the pediatric logistic organ dysfunction (PELOD) score. A prospective multicenter study. Lancet 2003:in press.
57. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. Journal of the National Cancer Institute 1959;22:719-48.
58. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple Organ Dysfunction Score: A reliable descriptor of a complex clinical outcome. Critical Care Medicine 1995;23:1638-52.
59. Parisot S, Pinaud P, Marchal C. Early septic shock and the use of naloxone in premature newborn infants [Choc septique précoce et emploi de la naloxone chez le nouveau-né prématuré]. Archives Francaises de Pediatrie 1986;43:149.
60. Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated Pediatric Risk of Mortility score. Critical Care Medicine 1996;24:743-52.
61. Pourriat JL, Pierrot M, Lapandry M, Cupa M. Naloxone in septic shock [La naloxone dans le choc septique]. Nouvelle Presse Medicale 1981;10:3793-4.
62. Prough DS, Roy R, Bumgarner J, Shannon G. Acute pulmonary edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology 1984;600:485-6.
63. Putterman C, Halpern P. Naloxone in circulatory shock. Klinische Wochenschrift 1987;65:926.
64. Safani M, Libby G. Naloxone therapy of septic shock. Critical Care Medicine 1985;13:875-6.
65. Siram S, Park SY. Naloxone in septic shock: Report of two cases. Journal of the National Medical Association 1984;76:713-6.
66. Swinburn WR, Phelan P. Response to naloxone in septic shock. Lancet 1982;1:167.
67. Tarelkina MN, Shirokov, Tsibin IN. Experience with using narcanti (naloxone) in patients with traumatic shock. Vestnik Khirurgii Imeni I I Grekova 1989;143:110-2.
68. Tiengo M. Naloxone in irreversible shock. Lancet 1980;2:690.
69. Unzueta Merino MC, Bonnin O, Cabrera Ruiz JC, Villar Landeira JM. Naloxone and cardiogenic shock. Revista Espanola de Anestesiologia Y Reanimacion 1987;34:446-9.
70. Valdivielso A, Casado Flores J, Ruiz Beltran A, Garcia Perez J, Garcia Onieva M, Hidalgo I. Naloxone and endotoxic shock: A wonder drug?. Annales Espaňoles de Pediatría 1984;20:85-90.
71. Wichman MW, Zellweger R, Ayala A, Chaudry IH. Effect of naloxone on immune responses after hemorrhagic shock. Critical Care Medicine 2000;28:184-9.
72. Wright DJ, Phillips M, Weller MPI. Naloxone in shock. Lancet 1980;2:1361.
73. Xing R, Yi X, Guang-Min L, Yuan-Wen W. Naloxone for haemorrhagic fever shock?. Tropical Doctor 1990;20:72-3.
74. Yeston NS, Grasberger RC, McIntosh TK. Naloxone in reversal of hypotension in septic shock. JAMA 1983;250:2287.
75. Boeuf B, Gauvin F, Guerguerian AM, Farrell C, Lacroix J, Jenicek M. Therapy of shock with naloxone: A meta-analysis. Critical Care Medicine 1998;26(11):1910-6.